APOPTOTIC PROTEINS AND CANCER: MANY FACES
AbstractComplex genetic and epigenetic alterations that disruptthe physiological regulation of apoptosis are thought tobe strategically critical for the carcinogenic process andare thought to provide survival and growth advantagesfor cancerous cells. Targeting and the induction ofapoptosis (programmed cell death) is an attractive targetfor successful cytotoxic therapy for many different typesof cancer, including leukaemias and lymphomas.1,2Bcl-2 proteinIn normal liver cells, Bcl-2 family members haveessential roles in liver homeostasis. On other hand, incarcinogenesis, these proteins play a significant role bysuppressing apoptotic death rather than stimulating cellproliferation. The up-regulation of either Bcl-2 or BclxL in mouse liver has been shown to protect hepatocytesfrom Fas-induced apoptosis and, therefore, liverdestruction in a dose-dependent manner.3 Recent datafrom our work demonstrated the protein expression ofcytoplasmic Bcl-2 in 16% of chronic HCV patients withno hepatocellular carcinoma (HCC) versus 8% inpatients with HCC.4 In HCC, Bcl-2 is significantlydown-regulated while Bcl-xL is predominatelyexpressed.5 However, Fiorentino et al reportedconsistent increased level of Bcl-2 RNA in HCC whichmay be suggest a post-transcription down-regulation ofBcl-2 at the protein level.5Another interesting finding was the delay ofliver tumour development in concordance with Bcl-2up-regulation in TGFα/Bcl-2 double transgenic mice6which appears to inhibit c-myc-induced livercarcinogenesis7. However, the in vivo electrophoretictransfer of Bcl-2 antisense oligonucleotide (ASO) intoliver demonstrated inhibitory effects on HCC in ratmodels.8 The deferential expression of Bcl-2 with theregards to tumours development could be contributed tothe expression status of p53. The expression of Bcl-2 issignificantly up-regulated in p53-positive HCC tissuewhile down-regulated in p53-negative tissues.9Changes in p53 and Bcl-2 protein expressionare a molecular hallmarks during hepatocarcinogenesis10that occur in concordance with high expression of theproliferating cell nuclear antigen (PCNA) and loss ofdifferentiation and HCC progression.11 The PCNAexpression is significantly elevated in late G1 and Sphases of proliferating cells, and has been used as abiomarker for progression in different types of cancersincluding HCC.12 The PCNA over-expression was evenconsidered as an indicator for increased risk of HCCdevelopment in HCV-infected patients.13,14Additionally, it was demonstrated that the celldivision rate and subsequently the size of thymocytespopulation in vivo is significantly reduced by theexpression of Bcl-2 or Bcl-xL in some reports15 whilethese two proteins can also inhibit apoptosis of dividingcells16. Bradly et al demonstrated that over-expressionof Bax and Bcl-2 in T-cell of transgenic mice can resultin disturbing the cell cycle of dividing thymocytes. Itwas found that while Bax has stimulatory effects, Bcl-2has inhibitory effects on cell cycle of cyclingthymocytes. Furthermore, in activated T-cells, Bcl-2overxpression was seen to delay the protein degradationof the tumour suppressor gene p27, whereas Baxaccelerated that.17Haemopoitic stem cells (HSC) with overexpressed Bcl-2 in Bcl-2-transgenic mice generated byDemon et al were reported to remain viable after growthfactor withdrawal whereas HSC from WT mice did notsurvive in the absence of growth factor. It wasdemonstrated that HSC from Bcl-2-transgenic miceresponded to pro-growth factors (such as IL-1, IL-3, IL-6, SCF and Flt3-ligand) with significantly faster andmore extensive proliferation with more delay in the cellcycle entry when compared with that from WT mice.Interestingly, when cultured with SCF, only 20% of WTHSC remained viable after one week, while HSC fromBcl-2-transgenic mice demonstrated greater survivalcapabilities and more extensive proliferation. It wasconcluded that over-expression of Bcl-2 and SCF/c-kitsignalling pathway are sufficient for HSC proliferation.However, one should note that proliferation alsoparticipated into the transformation of progenitor cells tothe myeloid lineage.18,19P53, Fas and Apaf-1A study by our group pointed out that in blast crisis(BC) of chronic myeloid leukaemia (CML) the p53expression is significantly increased when comparedwith the chronic phase of CML.20 Interestingly, whilerelatively high p53 expression was in general detectedJ Ayub Med Coll Abbottabad 2012;24(1)112 http://www.ayubmed.edu.pk/JAMC/24-1/Faris.pdfalong with up-regulation of apoptosis activating factor(Apaf-1), a significant down-regulation of Apaf-1 wasoddly seen when p53 had become clearly over-expressedsuggesting a disturbance in the p53 pathway (11, CMLpaper). Data from our group suggested decreasedexpression level of p53 and Apaf-1 in patients withBC.21 It seems that the Apaf-1 up-regulation by severaloncoproteins such as E2F1 is mechanistically critical forfacilitating the apoptosome assembly. Furthermore,Kannan et al demonstrated the presence of pointmutation, deletions and other genomic rearrangementsof p53 gene in 25% of BC and that p53 is an upstreamregulator of Apaf-1.22 In fact, we previously suggested alink between increased expression of p53, decreasedexpression of Apaf-1 and lack of Fas expression in onehand and progression of CML. Therefore, one should becareful towards understanding the significant upregulation of these pro-apoptotic genes in BCtransformation as well as in response to therapeuticapproaches.For any normally growing cell populationmolecular defects either at gene level, mRNA level orprotein level for genes regulating proliferation andapoptosis during cell cycle can interfere with thebalance between cell division and apoptosis for thatcellular population in vivo and provide strategicallyadvantageous scenario for carcinogenesis.23 Ourprevious results indicates that apoptosis (via Fas-FasL)play a role in regulating haemopoietic progenitor cellkinetics in humans as it does in mice. It also showed thatcaspases activation was required for the myeloidmaturation.24,25Cell cycle proteinsGenes regulating apoptosis have significant impact onthe cell cycle. A number of studies demonstrated thatcell-cycle regulators could interconnect withproliferation and apoptosis.Both p16–/– and p21–/– mice are deficient in keycell cycle genes, while lpr and gld mice (Fas and FasLmutant mice, respectively) have a defective apoptoticmechanism.24 However, Lewis et al26 showed that p16–/–knockout mice have a higher self-replication capacitythan do wild-type (WT) mice, which links the cell cycleand apoptosis. Similarly, p21–/– knockout mice have ahigher self-replication capacity (i.e., cell proliferation)than do WT mice.We showed that both lpr and gld mice have ahigher self-replication (i.e., cell proliferation) capacitythan do WT mice, which links apoptosis andproliferation.24 Miyashita et al27 showed that therestoration of p53 function resulted in down-regulationof Bcl-2 levels and the occurrence of apoptosis. Theyalso showed that p53 activates the Bax promoter andinduces high levels of Bax mRNA and protein.Moreover, Yin et al28 showed that Bax is required for50% of p53-induced apoptosis. Gomez et al29demonstrated a relationship between p27, cdk2 andapoptosis in thymocytes, which was modulated by p53,Bcl-2 and Bax. Thus, cdk2 activation seems to be thekey point at which the cell cycle and apoptosis meet.Janicke et al30 showed that the retinoblastoma(RB) gene is cleaved during apoptosis, at the caspaseconsensus cleavage site (DEAD), resulting in a proteinproduct of 50 kDa. Dou et al31 showed that RB is alsocleaved on an interior site, producing proteins of 48 and68 kDa. Fattman et al32 demonstrated that caspase-3 andcaspase-7 cleave RB at the DSID cleavage site, resultingin proteins of 68 and 48 kDa.These findings support a two-step model forRB cleavage and a promoting role in chemotherapymediated apoptosis. Browne et al33 demonstrated thatRB is cleaved at the carboxyl terminal, producing 43-and 30-kDa protein fragments. In addition, ZVAD wasfound to inhibit the cleavage of RB, poly-ADP-ribosepolymerase (PARP) and apoptosis. In contrast, YVADdid not inhibit primary carboxyl terminal cleavage ofRB and PARP. These results suggest that differentcaspases are responsible for the cleavage of differentsubstrates during apoptosis.In contrast, Suzuki and colleagues34demonstrated that survivin interacts with cdk4, and, as aresult, p21 is released from its complex with cdk4 andinteracts with pro-caspase-3 in mitochondria, resultingin inhibition of apoptosis. Cell-cycle transitions aremediated through multiple phosphorylations of cyclincdk complexes. RB phosphorylation releases E2Ftranscription factor, which activates certain genes duringS phase. Activation of p21 results in negative regulationof the cell cycle. P21 interacts with cdk and PCNA,
Alenzi FQ. Apoptosis and Diseases; Regulation and Clinical
Relevance (REVIEW). Saudi Med J 2005;26:1679–90.
Alenzi FQ. Links between apoptosis, cell cycle and proliferation
(REVIEW). Br J Biomed Sci 2004;61(2):99–102.
Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli
P. A bcl-2 transgene expressed in hepatocytes protects mice from
fulminant liver destruction but not from rapid death induced by
anti-Fas antibody injection. J Exp Med 1996;183:1031–6.
Alenzi FQ, El-Nashar EM, Al-Ghamdi SS, Abbas MY, Hamad
AM, El-Saeed OM, et al. Investigation of Bcl-2 and PCNA in
Hepatocellular Carcinoma: Relation to Chronic HCV. J Egypt
Natl Canc Inst 2010;22(1):87–94.
Fiorentino M, D’Errico A, Altimari A, Barozzi C, Grigioni WF.
High levels of BCL-2 messenger RNA detected by in situ
J Ayub Med Coll Abbottabad 2012;24(1)
hybridization in human hepatocellular and cholangiocellular
carcinomas. Diagn Mol Pathol 1999;8:189–94.
Vail ME, Pierce RH, Fausto N. Bcl-2 delays and alters hepatic
carcinogenesis induced by transforming growth factor alpha.
Cancer Res 2001;61:594–601.
de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van
Dyke T, et al. Paradoxical inhibition of c-myc-induced
carcinogenesis by Bcl-2 in transgenic mice. Cancer Res
Baba M, Iishi H, Tatsuta M. In vivo electroporetic transfer of bcl-
antisense oligonucleotide inhibits the development of
hepatocellular carcinoma in rats. Int J Cancer 2000;85:260–6.
Chiu CT, Yeh TS, Hsu JC, Chen MF. Expression of Bcl-2 family
modulated through p53-dependent pathway in human
hepatocellular carcinoma. Dig Dis Sci 2003;48:670–6.
Hussein MR. Alterations of p53, Bcl-2, and hMSH2 protein
expression in the cirrhotic, macro regenerative, dysplastic
nodules and hepatocellular carcinomas in Upper Egypt. Liver Int
Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, et
al. Down-regulation of tumor suppressor gene PTEN,
overexpression of p53, plus high proliferating cell nuclear antigen
index predict poor patient outcome of hepatocellular carcinoma
after resection. Oncol Rep 2007;18:1417–26.
Akyol P, Mittal S, Protić M, Oryhon J, Korolev SV, Joachimiak
A, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of
the genome. Int J Radiat Biol 2001;77:1007–21.
Dutta O, Ariza A, Llatjos M, Castella E, Mate JL, Navas-Palacios
JJ. Proliferating cell nuclear antigen expression in normal,
regenerative and neoplastic liver: A fine needle aspiration
cytology and biopsy study. Hum Pathol 1993;24:905–8.
Ballardini G, Groff P, Zoli M, Bianchi G, Giostra F, Francesconi
R, et al. Increased risk of hepatocellular carcinoma development
in patients with cirrhosis and with high hepatocellular
proliferation. J Hepatol 1994;20:218–22.
O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-
and its homologues influence control of cell cycle entry.
EMBO J 1996;15:6979.
Strasser A, Harris AW, Jacks T, Cory S. DNA damage can
induce apoptosis in proliferating lymphoid cells via p53-
independent mechanisms inhibitable by Bcl-2 Cell 1994;79:189.
Brady HJ, Gil Gomez G, Kirberg J, Berns AJ. Bax alpha perturbs
T cell development and affects cell cycle entry of T cells. EMBO
Domen J, Weissman IL. Hematopoietic stem cells need two
signals to prevent apoptosis; BCL-2 can provide one of these,
Kitl/c-Kit signaling the other. J Exp Med 2000;192:1707.
Domen J, Cheshier SH, Weissman IL. The role of apoptosis in
the regulation of hematopoietic stem cells: Overexpression of
Bcl-2 increases both their number and repopulation potential. J
Exp Med 2000;191:253.
Bi S, Lanza F, Goldman JM. The abnormal p53 proteins
expressed in CML cell lines are non-functional. Leukaemia.
Alenzi FQ, Wyse RK, Tamimi WG, Bamaga MS, Lotfy M. A
close link between Fas, p53 and Apaf-1 in chronic myeloid
leukemia. Saudi Med J 2007;28(7):1119–21.
Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio
N, Givol D. DNA microarray analysis of genes involved in p53
mediated apoptosis: activation of Apaf-1. Oncogene
Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K
et al. p53 in chronic myelogenous leukemia in acute phase. Proc
Natl Acad Sci USA 1991:88:6293–7.
Alenzi FQ, Marley S, Chandrashekran A, Botto M, Warrens A,
Goldman J. Regulation of haemopoietic progenitor cell number
by the Fas/FasL apoptotic mechanism Exp Hematol
Alenzi FQ, Al-Ghamdi SM, Tamimi WG, Al-Sebiany AM, ElNashar IM, El-Tounsi I, et al. Apoptosis role of FAS/FAS ligand
system in the regulation of myelopoiesis. Yale J Biol Med
Lewis JL, Chinswangwatanakul W, Zheng B, Marley SB,
Nguyen DX, Cross NC, et al. The influence of INK4 proteins on
growth and self-renewal kinetics of hematopoietic progenitor
cells. Blood 2001;97:2604.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK,
Liebermann DA, et al. Tumor suppressor p53 is a regulator of
bcl-2 and bax Oncogene 1994;9:1799.
Yin C, Knudson CM, Korsmeyer SJ, van Dyke T. Bax
suppresses tumorigenesis and stimulates apoptosis in vivo.
Gil Gomez G, Berns A, Brady HJ. A link between cell cycle and
cell death: Bax and Bcl-2 modulate Cdk2 activation during
thymocyte apoptosis. EMBO J 1998;17(24):7209–18.
Janicke RU, Walker PA, Lin XY, Porter AG. Specific cleavage
of the retinoblastoma protein by an ICE-like protease in
apoptosis. EMBO J 1996;15(24):6969–78.
Dou QP. Putative roles of retinoblastoma protein in apoptosis.
Fattman CL, Delach SM, Dou QP, Johnson DE. Sequential Twostep cleavage of the retinoblastoma protein by caspase-3/-7
during etoposide-induced apoptosis. Oncogene
Browne SJ, MacFarlan M, Cohen GM, Paraskeva C. The
adenomatous polyposis coli protein and retinoblastoma protein
are cleaved early in apoptosis and are potential substrates for
caspases. Cell Death Differ 1998;5(3):206–13.
Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi
Y, et al. Survivin initiates procaspase 3/p21 complex formation
as a result of interaction with Cdk4 to resist Fas-mediated cell
death. Oncogene 2000;19:1346–53.
Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-
-induced apoptosis of leukemia cells from patients with adult Tcell leukaemia. Blood 1993;81:2972–7.
Westendorf JJ, Lammert LM, Jelinek DF. Expression and
function of Fas (APO-1/CD95) in patient myeloma cells and
myeloma cell lines. Blood 1995;85:3566.
Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV.
Expression and function of the FAS antigen in B chronic
lymphocytic leukemia and hairy cell leukemia. Leukemia
Komada Y, Zhou YW, Zhang XL, Xue HL, Sakai H, Tanaka S,
et al Fas receptor (CD95)-mediated apoptosis is induced in
leukemic cells entering G1B compartment of the cell cycle.
Narikazu Iijima, Miyamura K, Itou T, Tanimoto M, Sobue R,
Saito H, et al, Functional Expression of Fas (CD95) in Acute
Myeloid Leukemia Cells in the Context of CD34 and CD38
Expression: Possible Correlation With Sensitivity to
Chemotherapy Blood 1997:90(12):pp. 4901–9.
Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke
RC. A role for CD95 ligand in preventing graft rejection. Nature
Buik RN, Till JE, McCulloch EA. Colony assay for proliferation
blast cells circulating in myeloblastic leukemia. Lancet
Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis
K, et al. Ionizing radiation sensitizes erythroleukemic cells but
not normal erythroblasts to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by
selective up-regulation of TRAIL-R1. Blood 2001;97:2596–603.
Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler
HG. Expression and function of CD95 (FAS/APO-1) in leukaemialymphoma tumour lines. Br J Haematol 1997;96:584–93.
Dong J, Naito M, Mashima T, Jang WH, Tsuruo T. Genetically
recessive mutant of human monocytic leukemia U937 resistant to
tumor necrosis factor-alpha-induced apoptosis. J Cell Physiol
J Ayub Med Coll Abbottabad 2012;24(1)
Shiiki K, Yoshikawa H, Kinoshita H, Takeda M, Ueno A,
Nakajima Y, et al. Potential mechanisms of resistance to
TRAIL/Apo2 L-induced apoptosis in human promyelocytic
leukemia HL-60 cells during granulocytic differentiation. Cell
Death Differ 2000;7(10):939–46.
Tourneur L, Delluc S, Lévy V, Valensi F, Radford-Weiss I,
Legrand O, et al. Absence or Low Expression of Fas-Associated
Protein with Death Domain in Acute Myeloid Leukemia Cells
Predicts Resistance to Chemotherapy and Poor Outcome. Cancer
Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, et
al. Toso, a cell surface, specific regulator of Fas-induced
apoptosis in T cells. Immunity 1998;8(4):461–71.
ElTounsi E, Alenzi FQ. TOSO, an alternative resistance
mechanism to Fas induction of apoptosis in AML. Egypt J
Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in
cancer: patent review. Expert Opin Ther Pat 2010;20:1723–37.
Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S,
Inoue M, et al. Expression of IAP-family proteins in adult acute
mixed lineage leukemia (AMLL). Am J Hematol
ElTounsi E, Alenzi FQ. Increased expression of survivin in TNFrelated apoptosis inducing ligand (TRAIL) resistant AML. Egypt
J Hematol 2007;32(3):147–58.
Altieri DC, Marchisio PC. Survivin apoptosis: an interloper
between cell death and cell proliferation in cancer. Lab Invest
;79(11):1327–33. Erratum in Lab Invest 1999;79(12):1543.
Invernizzi R, Travaglino E, Benatti C, Malcovati L, Della Porta
M, Cazzola M, et al. Survivin expression, apoptosis and
proliferation in chronic myelomonocytic leukemia. Eur J
Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dörken B,
Tamm I. In vivo expression of survivin and its splice variant
surviving 2B: impact on clinical outcome in acute myeloid
leukemia. Int J Cancer 2006;119(6):1291–7.
Eltounsi I, Andreeff M. Deferential biological and biochemical
effects of TNF- related apoptosis inducing ligand on leukemic
and normal CD34+ hematopoietic cells. EJH 2002;28(1):
Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle
progression in glioma cells via extracellular signal transduction
kinase activation. Cancer Res 2000;60:1766–71.
Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al.
The alkylphospholipid perifosine induces apoptosis of human
lung cancer cells requiring inhibition of Akt and activation of the
extrinsic apoptotic pathway. Mol Cancer Ther 2007;6:2029–38.
Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel
U. Survivin and EPR-1 expression in acute leukemias: Prognostic
significance and review of the literature. Leuk Res
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting
death-inducing receptors in cancer therapy. Oncogene
Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokineregulated expression of survivin in myeloid leukemia. Blood
Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu
X. ASPP1 and ASPP2: common activators of p53 family
members. Mol Cell Biol 2004;24:1341–50.
Zhao J, Wu G, Bu F, Lu B, Liang A, Cao L, et al. Epigenetic
silence of ankyrin-repeat–containing, SH3-domain-containing,
and proline-rich-region-containing Protein 1 (ASPP-1) and
ASPP-2 genes promotes tumor growth in hepatitis B viruspositive hepatocellular carcinoma. Hepatol 2010;51:142–53.
Trigiante G, Lu X. ASPP and cancer. Nat Rev Cancer
Sullivan A, Lu X. ASPP: A new family of oncogenes and tumor
suppressor genes. Br J Cancer 2007;96:196–200.
Alenzi FQ. Cell type specific expression of the apoptosis
stimulating protein (ASPP-2) in human tissues. Acta Microbiol
Immunol Hung 2010;57:419–29.
Kampa KM, Bonin M, Lopez CD. New insights into the
expanding complexity of the tumor suppressor ASPP2. Cell
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.